NEORX(nerx) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEORX(nerx)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SemiBull who wrote (648)	5/20/2002 7:58:13 PM
From: SemiBull	of 661

NeoRx Pretarget Lymphoma Product Well Tolerated In Phase I SEATTLE -(Dow Jones)- Data from a phase I clinical study indicated that NeoRx Corp.'s pretarget lymphoma therapy was well-tolerated in patients with non-Hodgkin's lymphoma and may provides a means to deliver higher doses of radiotherapeutic to tumor cells. In a press release Monday, the cancer therapeutics company said the Food and Drug Administration requested that it complete a 90-day follow-up on all patients treated to date. The FDA will review the data and any related matters before NeoRx conducts additional studies on pretarget lymphoma. The phase I clinical trial involved 15 non-Hodgkin's lymphoma patients who were heavily pretreated and had failed prior therapies. Two patients achieved a complete response, and two achieved a partial response, resulting in an overall response rate of 36%. Two patients who had undergone previous multiple bone marrow-suppressive therapies. A third patient was hospitalized for gastrointestinal complications, subsequently resolved. Shares of NeoRx traded recently at $2.53, up 8 cents, or 3.2%, on Nasdaq volume of 53,600 shares. Average daily volume is 54,635 shares. Company Web site: neorx.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next